Drugs / MD-7246
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03931785 | May 2019 → Feb 2020 | irritable bowel syndrome | Ironwood Pharmaceuticals, Inc. | Completed | Missed primary |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2021-05-24 | Ironwood Pharmaceuticals, Inc. | Results More Than a Third of Surveyed IBS-C Patients Reported That Their Symptoms Worsened During COVID-19 According to New Survey Findings Presented by Ironwood Pharmaceuticals at Digestive Disease Week® (DDW) ironwoodpharma.com ↗
Impact of MD-7246 on Irritable Bowel Syndrome with Diarrhea: Phase 2 Results |
| 2020-05-27 | Ironwood Pharmaceuticals, Inc. | Results Ironwood and AbbVie Report Top-line Phase II Data for MD-7246 in Patients with Abdominal Pain Associated with Irritable Bowel Syndrome with Diarrhea (IBS-D) ironwoodpharma.com ↗
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a GI-focused healthcare company, today announced top-line data from a Phase II trial evaluating MD-7246 in adult patients with abdominal pain associated with irritable bowel syndrome with diarrhea (IBS-D). |
| 2019-10-28 | Ironwood Pharmaceuticals, Inc. | Results Ironwood Pharmaceuticals to Highlight New Data at the American College of Gastroenterology 2019 Annual Scientific Meeting ironwoodpharma.com ↗
Phase I data demonstrating the limited effect of MD-7246 on bowel frequency and stool consistency in healthy volunteers will be presented in a poster session. |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2021-05-24 | Ironwood Pharmaceuticals, Inc. | More Than a Third of Surveyed IBS-C Patients Reported That Their Symptoms Worsened During COVID-19 According to New Survey Findings Presented by Ironwood Pharmaceuticals at Digestive Disease Week® (DDW) ironwoodpharma.com ↗ |
| 2020-05-27 | Ironwood Pharmaceuticals, Inc. | Ironwood and AbbVie Report Top-line Phase II Data for MD-7246 in Patients with Abdominal Pain Associated with Irritable Bowel Syndrome with Diarrhea (IBS-D) ironwoodpharma.com ↗ |
| 2019-10-28 | Ironwood Pharmaceuticals, Inc. | Ironwood Pharmaceuticals to Highlight New Data at the American College of Gastroenterology 2019 Annual Scientific Meeting ironwoodpharma.com ↗ |
| 2019-06-03 | Ironwood Pharmaceuticals, Inc. | Ironwood Pharmaceuticals and Allergan Initiate Patient Dosing in Phase II Clinical Trial of MD-7246 in Patients with Abdominal Pain Associated with IBS-D ironwoodpharma.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MD-7246 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03931785 ↗ |
| Route | Oral | “administered orally” NCT03931785 ↗ |